BioPharma Credit (LSE:BPCR) Change In Receivables : $-9.8 Mil (TTM As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit Change In Receivables?

BioPharma Credit's change in receivables for the quarter that ended in Dec. 2022 was $26.0 Mil. It means BioPharma Credit's Accounts Receivable declined by $26.0 Mil from Jun. 2022 to Dec. 2022 .

BioPharma Credit's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.5 Mil. It means BioPharma Credit's Accounts Receivable increased by $0.5 Mil from Dec. 2022 to Dec. 2023 .

BioPharma Credit's Accounts Receivable for the quarter that ended in Dec. 2022 was $0.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BioPharma Credit's Days Sales Outstanding for the six months ended in Dec. 2022 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BioPharma Credit's liquidation value for the six months ended in Dec. 2022 was $94.0 Mil.

BioPharma Credit Change In Receivables Historical Data

The historical data trend for BioPharma Credit's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPharma Credit Change In Receivables Chart

BioPharma Credit Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

5.76

16.00

-9.80

-9.83

-0.48

BioPharma Credit Semi-Annual Data
	Jun17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Dec23
Change In Receivables	Get a 7-Day Free Trial							-26.17	16.37	-35.87	26.05	-

BioPharma Credit Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-9.8 Mil.

BioPharma Credit (LSE:BPCR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BioPharma Credit's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	115.194	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, BioPharma Credit's accounts receivable are only considered to be worth 75% of book value:

BioPharma Credit's liquidation value for the quarter that ended in Dec. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	120.527	-	26.563	+	0.75 * 0	+	0.5 * 0
=	94.0

BioPharma Credit Change In Receivables Related Terms

Thank you for viewing the detailed overview of BioPharma Credit's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BioPharma Credit Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Gresham Street, 6th Floor, London, GBR, EC2V 7NQ

Website

https://www.bpcruk.com

BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit Headlines

No Headlines